保誠(02378.HK):M&G股份擬准予上市的售股章程已呈交英國金融市場行為監管局
格隆匯9月25日丨保誠(02378.HK)公佈,保誠於2018年3月14日宣佈擬將分拆M&GPrudential,以形成兩間獨立的上市公司。
在擬議分拆完成後,股東將同時持有保誠及M&GPrudential的權益,屆時M&GPrudential將作為M&G於倫敦證券交易所主板市場買賣。
有關擬議分拆的通函及有關M&G普通股股份擬准予上市的售股章程已分別由保誠及M&G呈交英國金融市場行為監管局。當該通函及該售股章程獲金融市場行為監管局批准刊發後,預計為今日稍後時間,保誠將馬上作出進一步公告。有關分拆的擬議時間表及有關兩項業務的資料均將載入該公告及相關文件內。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.